Coccidioidomycosis can cause severe meningitis, requiring lifelong treatment. In this study, we sought to better understand the potential effect of pharmacogenomic testing on treatment outcomes of patients with coccidioidal meningitis. Of 13 patients with coccidioidal meningitis who underwent pharmacogenomic testing, 11 had genetic variants of CYP2C19 and CYP3A5 that affect antifungal efficacy. These results led to real-time treatment changes and future antifungal planning. Routine pharmacogenomic testing helps to avoid antifungal treatments that are futile or lead to adverse effects.
Keywords: antifungal treatment; coccidioidal meningitis; coccidioidomycosis; pharmacogenomics.
Pharmacogenomic testing is used for assessing genetic variation to predict a patient’s response to medications. Our findings from 11 of 13 patients with coccidioidal meningitis revealed genetic variants affecting therapeutic concentrations of medication used for treating coccidioidal meningitis.
© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.